Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.80 |
| ▸ | ANPEP | P15144 | 2/20 | 0.67 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.58 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.58 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | ALPI | P09923 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | XIAP | P98170 | 1/20 | 0.52 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.52 |
| ▸ | SCN4A | P35499 | 2/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | LAP3 | P28838 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2736189 | 1.00 | EPHX1 (0.80) | EPHX1ANPEPSLC6A2TAAR1MAOA | |
| SCHEMBL902633 | 1.00 | EPHX1 (0.80) | EPHX1ANPEPSLC6A2TAAR1MAOA | |
| SCHEMBL15476621 | 1.00 | EPHX1 (0.80) | EPHX1ANPEPSLC6A2TAAR1MAOA | |
| SCHEMBL18034347 | 1.00 | EPHX1 (0.80) | EPHX1ANPEPSLC6A2TAAR1MAOA | |
| Hydrochloric Acid SCHEMBL16279669 | 0.97 | EPHX1 (0.76) | EPHX1ANPEPSLC6A2TAAR1MAOA | |
| Hydrochloric Acid SCHEMBL31169575 | 0.97 | EPHX1 (0.76) | EPHX1ANPEPSLC6A2TAAR1MAOA | |
| Hydrochloric Acid SCHEMBL16279671 | 0.97 | EPHX1 (0.76) | EPHX1ANPEPSLC6A2TAAR1MAOA | |
| SCHEMBL16137191 | 0.93 | EPHX1 (0.70) | EPHX1ANPEPSLC6A2TAAR1MAOA | |
| SCHEMBL20466361 | 0.90 | EPHX1 (0.73) | EPHX1ANPEPSLC6A2TAAR1MAOA | |
| SCHEMBL4303544 | 0.90 | EPHX1 (0.73) | EPHX1ANPEPSLC6A2TAAR1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109912426-B | Intermediate for synthesizing anti-AIDS medicine intensifier cobicistat | 上海奥博生物医药股份有限公司（CN） | 2023-01-13 | — | — | CN | claimed |
| CN-107857877-B | High-fluidity polyhexamethylene adipamide modified base resin and preparation method thereof | 华峰集团有限公司 | 2020-09-04 | — | — | CN | claimed |
| CN-109912426-A | For synthesizing anti-AIDS pharmaceutical reinforcing agent than the new intermediate for taking charge of his (cobicistant) | 上海奥博生物医药技术有限公司 | 2019-06-21 | — | — | CN | claimed |
| US-20140051888-A1 | NOVEL STEREOISOMERIC MIXTURES, SYNTHESIS AND USES THEREOF | AMPAC FINE CHEMICALS LLC (US) | 2014-02-20 | — | — | US | claimed |
| EP-0973726-B1 | METHOD FOR SYNTHESIS OF RHIZOFERRIN | UNIV FLORIDA (US) | 2005-04-06 | — | — | EP | claimed |
| CN-116354864-A | Diamine containing intramolecular imide ring and aliphatic alkyl group, polyimide formed based on diamine, preparation method and application thereof | 天津科技大学 | 2023-06-30 | — | — | CN | disclosed |
| CN-109912426-B | Intermediate for synthesizing anti-AIDS medicine intensifier cobicistat | 上海奥博生物医药股份有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| CN-109912426-B | Intermediate for synthesizing anti-AIDS medicine intensifier cobicistat | 上海奥博生物医药股份有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| CN-107857877-B | High-fluidity polyhexamethylene adipamide modified base resin and preparation method thereof | 华峰集团有限公司 | 2020-09-04 | — | — | CN | disclosed |
| CN-109912426-A | For synthesizing anti-AIDS pharmaceutical reinforcing agent than the new intermediate for taking charge of his (cobicistant) | 上海奥博生物医药技术有限公司 | 2019-06-21 | — | — | CN | disclosed |
| CN-109912426-A | For synthesizing anti-AIDS pharmaceutical reinforcing agent than the new intermediate for taking charge of his (cobicistant) | 上海奥博生物医药技术有限公司 | 2019-06-21 | — | — | CN | disclosed |
| CN-107857877-A | High fluidity polyhexamethylene adipamide modified base material resin and preparation method thereof | 华峰集团有限公司 | 2018-03-30 | — | — | CN | disclosed |
| US-20040006049-A1 | Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases | SLIL BIOMEDICAL CORPORATION (US) | 2004-01-08 | — | — | US | disclosed |
| US-6649587-B1 | Cytostatic or cytocidal componenet conjugated to a polypeptide recognized and cleaved by enzymes such as prostate specific antigen (PSA) and cathepsin B | SLIL BIOMEDICAL CORPORATION | 2003-11-18 | — | — | US | disclosed |
| US-6613764-B1 | Compounds such as N,N-dibenzylphenylalanine benzyl ester, used as enzyme inhibitors; prophylaxis of lymphadenopathy associated virus, cancer and malaria | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2003-09-02 | — | — | US | disclosed |
| EP-1337504-A2 | NOVEL POLYAMINE ANALOG-AMINO ACID CONJUGATES USEFUL AS ANTICANCER AGENTS | Slil Biomedical Corporation (US) | 2003-08-27 | — | — | EP | disclosed |
| WO-2002091989-A2 | ANTIVIRAL THERAPIES USING POLYAMINE OR POLYAMINE ANALOG-AMINO ACID CONJUGATES | SLIL BIOMEDICAL CORPORATION (US) | 2002-11-21 | — | — | WO | disclosed |
| WO-2002038105-A2 | NOVEL POLYAMINE ANALOG-AMINO ACID CONJUGATES USEFUL AS ANTICANCER AGENTS | SLIL BIOMEDICAL CORPORATION (US) | 2002-05-16 | — | — | WO | disclosed |
| EP-1173223-A2 | CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES | Slil Biomedical Corporation (US) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000066175-A2 | CONJUGATES AS THERAPIES FOR CANCER AND PROSTATE DISEASES | SLIL BIOMEDICAL CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051888-A1 | NOVEL STEREOISOMERIC MIXTURES, SYNTHESIS AND USES THEREOF | DDT, DPYD, DHPS | EPHX1 639/4885ANPEP 814/4885SLC6A2 2951/4885 |
| US-20040006049-A1 | Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases | CTSB, CTSL, CTSV | EPHX1 1504/4885ANPEP 69/4885SLC6A2 2035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.